These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26530375)

  • 1. The Actual Role of Receptors as Cancer Markers, Biochemical and Clinical Aspects: Receptors in Breast Cancer.
    Brennan M; Lim B
    Adv Exp Med Biol; 2015; 867():327-37. PubMed ID: 26530375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validated biomarkers: The key to precision treatment in patients with breast cancer.
    Duffy MJ; O'Donovan N; McDermott E; Crown J
    Breast; 2016 Oct; 29():192-201. PubMed ID: 27521224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Breast Cancer Biomarkers: Challenges in Routine Estrogen Receptor, Progesterone Receptor, and HER2/neu Evaluation.
    Jorns JM
    Arch Pathol Lab Med; 2019 Dec; 143(12):1444-1449. PubMed ID: 31373514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal Receptor and HER2 Analyses for Breast Cancer Using Cell Blocks in Routine Work: Experience at Our Institution].
    Nishimura R
    Rinsho Byori; 2015 Mar; 63(3):319-21. PubMed ID: 26524854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 status in elderly women with breast cancer.
    Laird-Fick HS; Gardiner JC; Tokala H; Patel P; Wei S; Dimitrov NV
    J Geriatr Oncol; 2013 Oct; 4(4):362-7. PubMed ID: 24472480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer.
    Van Poznak C; Tan L; Panageas KS; Arroyo CD; Hudis C; Norton L; Seidman AD
    J Clin Oncol; 2002 May; 20(9):2319-26. PubMed ID: 11981003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular characterization of breast cancer in clinical practice].
    Zemmouri Y; De Croze D; Vincent Salomon A; Rouzier R; Bonneau C
    Gynecol Obstet Fertil; 2016 May; 44(5):285-92. PubMed ID: 27150068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alteration of immunohistochemical biomarkers between pre- and post-chemotherapy: hormone receptors, HER2 and Ki-67.
    Kumaki N; Umemura S; Tang X; Saito Y; Suzuki Y; Tokuda Y
    Breast Cancer; 2011 Apr; 18(2):98-102. PubMed ID: 21290265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic and predictive factors in breast cancer].
    Bozhok AA; Semiglazov VF; Semiglazov VV; Arzumanov AS; Klettsel' AE
    Vopr Onkol; 2005; 51(4):434-43. PubMed ID: 16308974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ribociclib in HR-positive, HER2-negative breast cancer.
    Burki TK
    Lancet Oncol; 2016 Nov; 17(11):e482. PubMed ID: 27746106
    [No Abstract]   [Full Text] [Related]  

  • 13. A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response.
    Viale G
    Breast; 2015 Nov; 24 Suppl 2():S23-5. PubMed ID: 26255744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncotype DX test on unequivocally HER2-positive cases: potential for harm.
    Bhargava R; Dabbs DJ
    J Clin Oncol; 2012 Feb; 30(5):570-1. PubMed ID: 22231038
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
    Calhoun BC; Collins LC
    Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of estrogen and progesterone receptor and neu expression in breast carcinoma.
    Chu JS; Lee WJ; Chen KM; Hsu HC
    J Formos Med Assoc; 1994 Apr; 93(4):277-82. PubMed ID: 7914767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of estrogen receptor, progesterone receptor, and HER-2/neu analysis of multiple foci in multifocal ipsilateral invasive breast carcinoma.
    East EG; Pang JC; Kidwell KM; Jorns JM
    Am J Clin Pathol; 2015 Dec; 144(6):952-9. PubMed ID: 26573003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer.
    Hammond ME; Hayes DF; Wolff AC
    J Clin Oncol; 2011 May; 29(15):e458. PubMed ID: 21502545
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.